周年综述：奥曲肽，40 年后。
ANNIVERSARY REVIEW: Octreotide, 40 years later.
机构信息
Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
出版信息
Eur J Endocrinol. 2019 Nov;181(5):R173-R183. doi: 10.1530/EJE-19-0074.
PMID:31398712
Abstract
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years of clinical use of octreotide, including the application of radiolabeled forms of the peptide.
摘要
奥曲肽在开发 40 年后仍然是一种常用的药物，用于治疗肢端肥大症和 GEP-NETs。在此期间，很少有与该药物竞争的创新药物出现。本文讨论了奥曲肽 40 年临床应用的几个方面，包括放射性标记肽的应用。
Zotero 插件